NCT01405833View on ClinicalTrials.gov

Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Sciatica
Interventions
DRUG

BG00010 (Neublastin)

Multiple doses, weight-based IV administration

DRUG

Placebo

Single dose IV matched placebo

Trial Locations (1)

Unknown

Research Site, Leiden

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT01405833 - Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica. | Biotech Hunter | Biotech Hunter